These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35689366)

  • 1. Effectiveness of change from suvorexant to lemborexant drug in the treatment of sleep disorders.
    Okino K; Suzuki H; Kondo S; Tomioka H; Tokumasu T; Yamada H; Iwanami A; Inamoto A
    Psychogeriatrics; 2022 Sep; 22(5):595-604. PubMed ID: 35689366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lemborexant, an orexin receptor antagonist sedative-hypnotic: Is it useful for insomnia in psychiatric disorders?
    Keks NA; Hope J
    Australas Psychiatry; 2022 Aug; 30(4):530-532. PubMed ID: 35491942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Transitioning to Lemborexant from Z-drug, Suvorexant, and Ramelteon in Japanese Insomnia Patients: An Open-label, Multicenter Study.
    Ozone M; Hirota S; Ariyoshi Y; Hayashida K; Ikegami A; Habukawa M; Ohshima H; Harada D; Hiejima H; Kotorii N; Murotani K; Taninaga T; Uchimura N
    Adv Ther; 2024 Apr; 41(4):1728-1745. PubMed ID: 38460107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventive Effects of Ramelteon, Suvorexant, and Lemborexant on Delirium in Hospitalized Patients With Physical Disease: A Retrospective Cohort Study.
    Henmi R; Nakamura T; Mashimoto M; Takase F; Ozone M
    J Clin Psychopharmacol; 2024 Jul-Aug 01; 44(4):369-377. PubMed ID: 38820374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience.
    Matsumura T; Terada J; Yoshimura C; Koshikawa K; Kinoshita T; Yahaba M; Nagashima K; Sakao S; Tatsumi K
    Drug Des Devel Ther; 2019; 13():809-816. PubMed ID: 30880914
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.
    McElroy H; O'Leary B; Adena M; Campbell R; Monfared AAT; Meier G
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1296-1308. PubMed ID: 34121443
    [No Abstract]   [Full Text] [Related]  

  • 7. Lemborexant vs suvorexant for insomnia: A systematic review and network meta-analysis.
    Kishi T; Nomura I; Matsuda Y; Sakuma K; Okuya M; Ikuta T; Iwata N
    J Psychiatr Res; 2020 Sep; 128():68-74. PubMed ID: 32531478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.
    Rosenberg R; Murphy P; Zammit G; Mayleben D; Kumar D; Dhadda S; Filippov G; LoPresti A; Moline M
    JAMA Netw Open; 2019 Dec; 2(12):e1918254. PubMed ID: 31880796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence-based insomnia treatment strategy using novel orexin antagonists: A review.
    Kishi T; Nishida M; Koebis M; Taninaga T; Muramoto K; Kubota N; Moline M; Sakuma K; Okuya M; Nomura I; Iwata N
    Neuropsychopharmacol Rep; 2021 Dec; 41(4):450-458. PubMed ID: 34553844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia.
    Patel KV; Aspesi AV; Evoy KE
    Ann Pharmacother; 2015 Apr; 49(4):477-83. PubMed ID: 25667197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating lemborexant for the treatment of insomnia.
    Zammit G; Krystal A
    Expert Opin Pharmacother; 2021 Jul; 22(10):1235-1243. PubMed ID: 33711243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Review of Lemborexant to Treat Insomnia.
    Fuller MC; Carlson SF; Grant C; Berry V; Ivancich M; Cornett EM; Kaye AM; Viswanath O; Urits I; Shekoohi S; Kaye AD
    Psychopharmacol Bull; 2024 Mar; 54(1):43-64. PubMed ID: 38449475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suvorexant for insomnia in patients with psychiatric disorder: A 1-week, open-label study.
    Kishi T; Sakuma K; Okuya M; Ninomiya K; Oya K; Kubo M; Matsui Y; Nomura I; Okuyama Y; Matsunaga S; Iwata N
    Neuropsychopharmacol Rep; 2019 Sep; 39(3):252-255. PubMed ID: 31283862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Suvorexant for the treatment of primary insomnia: A systematic review and meta-analysis.
    Kuriyama A; Tabata H
    Sleep Med Rev; 2017 Oct; 35():1-7. PubMed ID: 28365447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suvorexant in Patients With Insomnia: Results From Two 3-Month Randomized Controlled Clinical Trials.
    Herring WJ; Connor KM; Ivgy-May N; Snyder E; Liu K; Snavely DB; Krystal AD; Walsh JK; Benca RM; Rosenberg R; Sangal RB; Budd K; Hutzelmann J; Leibensperger H; Froman S; Lines C; Roth T; Michelson D
    Biol Psychiatry; 2016 Jan; 79(2):136-48. PubMed ID: 25526970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lemborexant for the Treatment of Insomnia: Direct and Indirect Comparisons With Other Hypnotics Using Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed.
    Citrome L; Juday T; Frech F; Atkins N
    J Clin Psychiatry; 2021 Jun; 82():. PubMed ID: 34077032
    [No Abstract]   [Full Text] [Related]  

  • 17. Suvorexant for insomnia: a systematic review of the efficacy and safety profile for this newly approved hypnotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
    Citrome L
    Int J Clin Pract; 2014 Dec; 68(12):1429-41. PubMed ID: 25231363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety profile and clinical course of patients with insomnia administered suvorexant by initial treatment status in a post-marketing survey.
    Sano H; Asai Y; Miyazaki M; Iwakura M; Maeda Y; Hara M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1109-1118. PubMed ID: 31478753
    [No Abstract]   [Full Text] [Related]  

  • 19. Prompt improvement of difficulty with sleep initiation and waking up in the morning and daytime somnolence by combination therapy of suvorexant and ramelteon in delayed sleep-wake phase disorder: a case series of three patients.
    Izuhara M; Kawano K; Otsuki K; Hashioka S; Inagaki M
    Sleep Med; 2021 Apr; 80():100-104. PubMed ID: 33588260
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suvorexant for the Treatment of Insomnia in Adolescents.
    Kawabe K; Horiuchi F; Ochi M; Nishimoto K; Ueno SI; Oka Y
    J Child Adolesc Psychopharmacol; 2017 Nov; 27(9):792-795. PubMed ID: 28520464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.